Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials: iFeTiS Consensus Statement

Sagar R, Almeida-Porada G, Blakemore K, Chan JK, Choolani M, Götherström C, Jaulent A, MacKenzie TC, Mattar C, Porada CD, Peranteau WH, Schneider H, Shaw SW, Waddington SN, Westgren M, David AL (2020)

Publication Type: Journal article, Review article

Publication year: 2020

Journal

Molecular Therapy Cell Press

DOI: 10.1016/j.ymthe.2020.10.012

Authors with CRIS profile

Holm Schneider Professur für Kinderheilkunde/Experimentelle Perinatalmedizin

Involved external institutions

Wake Forest School of Medicine US United States (USA) (US) EspeRare CH Switzerland (CH) University College London (UCL) GB United Kingdom (GB) Karolinska Institute SE Sweden (SE) NUS Yong Loo Lin School of Medicine SG Singapore (SG) Chang Gung Memorial Hospital TW Taiwan (TW) Children's Hospital of Philadelphia US United States (USA) (US) SingHealth Group / Singapore Health Services SG Singapore (SG) University of California San Francisco (UCSF) US United States (USA) (US)

How to cite

APA:

Sagar, R., Almeida-Porada, G., Blakemore, K., Chan, J.K., Choolani, M., Götherström, C.,... David, A.L. (2020). Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials: iFeTiS Consensus Statement. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2020.10.012

MLA:

Sagar, Rachel, et al. "Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials: iFeTiS Consensus Statement." Molecular Therapy (2020).

BibTeX: Download